EA200901402A1 - Терапевтическое средство против глаукомы, содержащее в качестве активного ингредиента производное аденозина - Google Patents

Терапевтическое средство против глаукомы, содержащее в качестве активного ингредиента производное аденозина

Info

Publication number
EA200901402A1
EA200901402A1 EA200901402A EA200901402A EA200901402A1 EA 200901402 A1 EA200901402 A1 EA 200901402A1 EA 200901402 A EA200901402 A EA 200901402A EA 200901402 A EA200901402 A EA 200901402A EA 200901402 A1 EA200901402 A1 EA 200901402A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
cycloalkyl
glaucoma
hydrogen atom
therapeuticol
Prior art date
Application number
EA200901402A
Other languages
English (en)
Other versions
EA015971B1 (ru
Inventor
Ацуси Симазаки
Норико Кавабата
Томоко Кирихара
Джейсон М. Риджер
Роберт Д. Томпсон
Original Assignee
Сантен Фармасьютикал Ко., Лтд.
ПГэксХЕЛТ, ЛЛК
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантен Фармасьютикал Ко., Лтд., ПГэксХЕЛТ, ЛЛК filed Critical Сантен Фармасьютикал Ко., Лтд.
Publication of EA200901402A1 publication Critical patent/EA200901402A1/ru
Publication of EA015971B1 publication Critical patent/EA015971B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к терапевтическому средству против глаукомы. Соединение общей формулы (1) или его соль обнаруживают превосходное понижающее действие на внутриглазное давление в испытании на снижение внутриглазного давления и применимы в качестве профилактического или терапевтического средства против глаукомы или глазной гипертензии.В указанной формуле Х представляет собой СН или N; Rпредставляет собой атом водорода, гидроксигруппу, атом галогена, алкильную группу, алкоксигруппу, циклоалкильную группу, циклоалкоксигруппу, (циклоалкил)алкоксигруппу илиRпредставляет собой атом водорода, алкильную группу, циклоалкильную группу, алкилкарбонильную группу или алкилоксикарбонильную группу; Rи Rявляются одинаковыми или различными и представляют собой атом водорода, гидроксигруппу, атом галогена, алкильную группу, алкоксигруппу, циклоалкильную группу или циклоалкоксигруппу.
EA200901402A 2007-04-16 2008-04-14 Терапевтическое средство против глаукомы, содержащее в качестве активного ингредиента производное аденозина EA015971B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007106915A JP2008266143A (ja) 2007-04-16 2007-04-16 アデノシン誘導体を有効成分として含有する緑内障治療剤
PCT/US2008/004770 WO2008130520A1 (en) 2007-04-16 2008-04-14 Therapeutic agent for glaucoma containing adenosine derivative as active ingredient

Publications (2)

Publication Number Publication Date
EA200901402A1 true EA200901402A1 (ru) 2010-04-30
EA015971B1 EA015971B1 (ru) 2012-01-30

Family

ID=39875791

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200901402A EA015971B1 (ru) 2007-04-16 2008-04-14 Терапевтическое средство против глаукомы, содержащее в качестве активного ингредиента производное аденозина

Country Status (15)

Country Link
US (2) US20100093770A1 (ru)
EP (1) EP2134174A4 (ru)
JP (2) JP2008266143A (ru)
KR (1) KR20090128495A (ru)
CN (1) CN101677544A (ru)
AU (1) AU2008241496A1 (ru)
BR (1) BRPI0809953A2 (ru)
CA (1) CA2684866A1 (ru)
EA (1) EA015971B1 (ru)
IL (1) IL201418A0 (ru)
MX (1) MX2009011076A (ru)
NZ (1) NZ580165A (ru)
UA (1) UA100376C2 (ru)
WO (1) WO2008130520A1 (ru)
ZA (1) ZA200906989B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985754B2 (en) * 2006-07-17 2011-07-26 Trovis Pharmaceuticals, Llc Selective antagonists of A2A adenosine receptors
HUE030566T2 (en) 2010-01-11 2017-05-29 Inotek Pharmaceuticals Corp Combination, kit and method for reducing intraocular pressure
JP2013523738A (ja) * 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション アデノシン化合物およびそれらの使用
SG184221A1 (en) 2010-03-26 2012-10-30 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
TW201309343A (zh) * 2011-02-10 2013-03-01 參天製藥股份有限公司 經改善親水性藥物之藥物移行性之水性組成物
MX2014009086A (es) 2012-01-26 2015-06-05 Inotek Pharmaceuticals Corp Polimorfos anhidros de nitrato de [ (2r,3s,4r,5r) -5- (6- (ciclopentilamino) -9h-purin-9-il) -3,4-dihidroxitetra-hidrofuran- 2-il) ] metilo y procesos para su preparación.
KR20150139501A (ko) 2013-03-15 2015-12-11 이노텍 파마슈티컬스 코포레이션 안과용 제형
WO2017137528A1 (en) 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Adenosine a1 receptor agonist for use in treatment of status epilepticus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
MXPA06002716A (es) * 2003-09-12 2006-06-06 Allergan Inc Metodos y composiciones para el tratamiento de dolor y otras condiciones mediadas por adrenergicos de alfa-2.
US7605143B2 (en) * 2004-08-02 2009-10-20 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
JP2008285478A (ja) * 2007-04-16 2008-11-27 Santen Pharmaceut Co Ltd アデノシンａ２ａ受容体アゴニストを有効成分として含有する緑内障治療剤

Also Published As

Publication number Publication date
EA015971B1 (ru) 2012-01-30
EP2134174A4 (en) 2011-05-25
IL201418A0 (en) 2010-06-16
UA100376C2 (en) 2012-12-25
JP2010524933A (ja) 2010-07-22
JP4923141B2 (ja) 2012-04-25
CN101677544A (zh) 2010-03-24
CA2684866A1 (en) 2008-10-30
EP2134174A1 (en) 2009-12-23
AU2008241496A1 (en) 2008-10-30
NZ580165A (en) 2012-07-27
US20100093770A1 (en) 2010-04-15
JP2008266143A (ja) 2008-11-06
ZA200906989B (en) 2010-06-30
MX2009011076A (es) 2010-01-20
BRPI0809953A2 (pt) 2014-09-23
US20130109646A1 (en) 2013-05-02
KR20090128495A (ko) 2009-12-15
WO2008130520A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
EA200901402A1 (ru) Терапевтическое средство против глаукомы, содержащее в качестве активного ингредиента производное аденозина
ME01421B (me) 5-supstituisani derivati kinazolinona kao protivtumorska sredstva
MY142807A (en) Benzimidazole derivative and use thereof.
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
TW200833675A (en) Nicotinamide derivatives
WO2007136116A3 (en) C-phenyl glycitol compound for the treatment of diabetes
WO2008083252A3 (en) Methods of use for cyclopamine analogs
PE20060583A1 (es) Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas
NO20085269L (no) 2-tioksantinderivater som fungerer som MPO-inhibitorer
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
UY29015A1 (es) Derivados de pirido-pirimidina, su preparacinn, su aplicacinn en terapeutica
NO20071008L (no) Fremgangsmate for fremstilling av N-piperidino-1,5-difenylpyrazol-3-karboksamidderivater
RU2011112684A (ru) АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α
MX2010001566A (es) Derivado de aminopirazolamida.
WO2006133928A3 (en) Use of phenylsemicarbazones for seed treatment
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
TW200734336A (en) 6-Heteroarylpyridoindolone derivatives, preparation thereof and therapeutic use thereof
WO2009041565A1 (ja) キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤
WO2006007227A3 (en) Abnormal cannabidiols for lowering intraocular pressure
MY146775A (en) Amino alcohol derivative and immunosuppressive agent having same as an active ingredient
TW200600013A (en) 5,6-Dialkyl-7-aminotriazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds
ATE511506T1 (de) Thiopen-derivate als wirkstoffe gegen okulare hypotonie
MX2009006266A (es) Procedimientos de preparacion de 3-(4-(2,4-difluorobenciloxi)-3-br omo-6-metil-2-oxopiridin-1 (2h)-il)-n,4-dimetilbenzamida.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU